Anthem Biosciences Reports Strong FY26 Performance, Plans Major Expansion

Anthem Biosciences has posted robust financial results for the fiscal year ending March 31, 2026. Full-year consolidated revenue saw a significant increase of 15.2% compared to the previous year, reaching ₹21,243 million. The company demonstrated strong profitability, achieving an EBITDA margin of 43.4% and a Profit After Tax (PAT) margin of 26.0% for the full fiscal year.

During the fourth quarter of FY26, revenue stood at ₹6,109 million. The company also reported healthy margins in the quarter, with an EBITDA margin of 48.1% and a PAT margin of 28.7%.

Why This Performance Matters

This strong financial performance suggests healthy demand for Anthem Biosciences' products and effective operational management. The consistent revenue growth and high profit margins are positive signals for investors. Furthermore, the company's commitment to future growth is highlighted by its planned greenfield expansion, aimed at enhancing manufacturing capacity.

Strategic Expansion Plans

Anthem Biosciences is moving forward with a substantial greenfield expansion project located in Harohalli, Bangalore. Phase I of this expansion will require an investment of ₹12,000 million. This project is set to significantly boost the company's capacity, adding 365 KL for Custom Synthesis and 100 KL for Fermentation operations.

Key Risks and Considerations

While the results are strong, Anthem Biosciences faces inherent risks. Successfully executing its ambitious expansion plans and securing necessary regulatory approvals will be critical. Investors should also monitor potential financial challenges, including managing cash flow projections and market fluctuations. The company is also keeping an eye on potential future accounting impacts related to evolving government Labour Codes.

Key Financial Metrics

• FY26 Consolidated Revenue: ₹21,243 Mn (15.2% YoY growth)
• FY26 EBITDA Margin: 43.4%
• FY26 PAT Margin: 26.0%
• Q4FY26 Revenue: ₹6,109 Mn
• Q4FY26 EBITDA Margin: 48.1%
• Q4FY26 PAT Margin: 28.7%
• Greenfield Expansion Phase I Investment: ₹12,000 Mn

What to Watch Next

Investors are advised to monitor the upcoming earnings call, scheduled for May 20, 2026, for further details and management insights. Tracking the progress and timeline of the greenfield expansion project will also be important for assessing future growth.